Leaps by Bayer’s Post

Diagnosing and treating autoimmune diseases remains a major challenge – but innovation is accelerating. In his latest op-ed for Forbes, Juergen Eckhardt, Head of Leaps by Bayer, highlights four novel approaches that could reshape the future of care for 320+ million people affected globally. ➡️ Coding Bio is working on scalable immune engager molecules – an "off-the-shelf" approach to eliminate autoreactive B cells, offering a promising alternative to the individualized nature of CAR T-cell therapy. ➡️ Nuvig Therapeutics Inc. is developing a drug that mimics the anti-inflammatory effects of sialylated IgGs, aiming to provide a more convenient and potent option than current IVIG infusions. ➡️ etherna, in collaboration with UHasselt, is advancing mRNA-based inverse vaccines that could retrain the immune system to tolerate self-antigens and prevent harmful autoimmune reactions. ➡️ Hansa Biopharma is developing enzymes that rapidly degrade IgG antibodies, potentially enabling faster-acting interventions for IgG-driven autoimmune diseases. 💡 Each of these technologies represents a shift toward more precise, targeted, and potentially disease-modifying treatments. 🔗 Read the full article in the comments to explore how these innovations may help us move beyond symptom control – and toward immune system reprogramming.